NCT03592706View on ClinicalTrials.gov

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2021

Study Completion Date

August 31, 2021

Conditions
HepatoCellular CarcinomaLiver Cancer
Interventions
BIOLOGICAL

IKC (Immune Killer Cells)

PROCEDURE

TACE (Transcatheter Arterial Chemoembolization)

Trial Locations (1)

Unknown

RECRUITING

Tri Service General Hospital, Taipei

Sponsors
All Listed Sponsors
collaborator

Tri-Service General Hospital

OTHER

lead

Ivy Life Sciences, Co., Ltd

INDUSTRY

NCT03592706 - Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | Biotech Hunter | Biotech Hunter